Sol-Gel to Present at Upcoming Healthcare Investor Conferences
Sol-Gel Technologies (NASDAQ: SLGL) announced its participation in two upcoming investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Sol-Gel Technologies (NASDAQ: SLGL) announced its participation in two upcoming investor conferences. The Jefferies Virtual Healthcare Conference will feature CEO Dr. Alon Seri-Levy, CFO Gilad Mamlok, and U.S. Head of Commercialization John Vieira on June 2, 2020, at 11:00 am ET. Additionally, the Raymond James Human Health Innovation Conference will take place on June 18, 2020, with Dr. Seri-Levy speaking at 11:40 am ET. Live webcasts will be available on Sol-Gel's website, which will also host archived recordings for around 30 days post-event.
Details
News Market Reaction – SLGL
The recorded move for SLGL in the trading session of this news was +1.09%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NESS ZIONA, Israel, May 27, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced the Company will present at the following upcoming investor conferences.
Jefferies Virtual Healthcare Conference
| Speakers: | Dr. Alon Seri-Levy, Chief Executive Officer |
| Gilad Mamlok, Chief Financial Officer | |
| John Vieira, U.S. Head of Commercialization | |
| Date: | June 2, 2020 |
| Time: | 11:00 am Eastern Time |
Raymond James Human Health Innovation Conference
| Speaker: | Dr. Alon Seri-Levy, Chief Executive Officer |
| Date: | June 18, 2020 |
| Time: | 11:40 am Eastern Time |
Sol-Gel’s senior management team will provide an overview of the Company and give a business update. Live webcasts of the presentations will be available under the “Events and Presentations” in the investors section of the Company’s website at www.sol-gel.com. An archived webcast recording of the events will be available on the website for approximately 30 days post presentation.
About Sol-Gel Technologies
Sol-Gel is a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Sol-Gel leverages its proprietary microencapsulation technology platform for Twyneo, for the treatment of acne vulgaris, and Epsolay, for the treatment of papulopustular rosacea. The Company’s pipeline also includes SGT-210, an early-stage topical epidermal growth factor receptor inhibitor, erlotinib, for the treatment of punctate palmoplantar keratoderma, and preclinical assets tapinarof and roflumilast. For additional information, please visit www.sol-gel.com.
For further information, please contact:
Sol-Gel Contact:
Gilad Mamlok
Chief Financial Officer
+972-8-9313433
Investor Contact:
Lee M. Stern
Solebury Trout
lstern@soleburytrout.com
Source: Sol-Gel Technologies Ltd.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.